HomeCompareHRDIL vs JNJ

HRDIL vs JNJ: Dividend Comparison 2026

HRDIL yields 1000000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HRDIL wins by $4.7683925249533696e+36M in total portfolio value
10 years
HRDIL
HRDIL
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full HRDIL calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — HRDIL vs JNJ

📍 HRDIL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHRDILJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HRDIL + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HRDIL pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HRDIL
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, HRDIL beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HRDIL + JNJ for your $10,000?

HRDIL: 50%JNJ: 50%
100% JNJ50/50100% HRDIL
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

HRDIL
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HRDIL buys
0
JNJ buys
0
No recent congressional trades found for HRDIL or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHRDILJNJ
Forward yield1000000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.7683925249533696e+36M$30.3K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$4.7683311610149396e+36M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HRDIL vs JNJ ($10,000, DRIP)

YearHRDIL PortfolioHRDIL Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,592$272.30+$100.00MHRDIL
2$934,786,450,701$934,679,439,252.34$11,289$357.73+$934786.44MHRDIL
3$8,165,787,108,578,292$8,164,786,887,076,042.00$12,123$472.89+$8165787108.57MHRDIL
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$13,141$629.86+$66665884190957.63MHRDIL
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$14,408$846.81+$508662171058048128.00MHRDIL
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$16,021$1,151.60+$3.62723524842849e+21MHRDIL
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$18,122$1,588.22+$2.417368115915061e+25MHRDIL
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$20,930$2,228.20+$1.5056740286145463e+29MHRDIL
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$24,792$3,191.91+$8.764771002818475e+32MHRDIL
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$4.7683925249533696e+36MHRDIL

HRDIL vs JNJ: Complete Analysis 2026

HRDILStock

Here Media Inc. offers original programming content tailored for the lesbian, gay, bisexual, and transgender (LGBT) community on a subscription basis. The company publishes magazines and books, as well as operates companion Websites targeting the LGBT community. Its products include the magazines Out, The Advocate, and HIVPlus, as well as books published by Alyson Books, which are distributed through traditional newsstands, other retail outlets, and by subscriptions of print and digital editions of the magazines. It also operates PlanetOut, an online media company serving the LGBT community through its website Gay.com, a social networking Website; and a companion Website, heretv.com that features original shows, podcasts, news, and other entertainment, as well as a library of LGBT-themed streaming video. In addition, the company provides subscription video-on-demand and/or regularly scheduled television channel services through cable, satellite, and fiber-optic television providers serving domestic television households in the United States; and syndicates free-to-the-user content to Websites, including msn.com and aol.com. It serves customers through cable television, direct-to-home satellite television, fiber-optic television, and the Internet under the brand name "here!". The company is was founded in 2009 and is headquartered in Los Angeles, California.

Full HRDIL Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this HRDIL vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HRDIL vs SCHDHRDIL vs JEPIHRDIL vs OHRDIL vs KOHRDIL vs MAINHRDIL vs ABBVHRDIL vs MRKHRDIL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.